EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress
Authors
Keywords
-
Journal
Cancer Cell International
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-19
DOI
10.1186/s12935-020-01260-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains
- (2019) Maria C. Donaldson-Collier et al. NATURE GENETICS
- Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation
- (2019) Anne Laugesen et al. MOLECULAR CELL
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
- (2018) Yanrong Su et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death
- (2017) Naoshad Muhammad et al. Oncotarget
- Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma
- (2016) Naoshad Muhammad et al. CLINICAL CANCER RESEARCH
- Recently discovered EZH2 and EHMT2 (G9a) inhibitors
- (2016) Uttara Soumyanarayanan et al. Future Medicinal Chemistry
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3
- (2016) Naoshad Muhammad et al. Oncotarget
- Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex
- (2015) Naoshad Mohammad et al. Scientific Reports
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors
- (2014) William Lee et al. NATURE GENETICS
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- The FOS Transcription Factor Family Differentially Controls Trophoblast Migration and Invasion
- (2013) Stephen J. Renaud et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex
- (2012) Ji Min Lee et al. MOLECULAR CELL
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
- (2012) Sharad K. Verma et al. ACS Medicinal Chemistry Letters
- An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
- (2010) Jindan Yu et al. CANCER CELL
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More